Cancer-related thrombosis, specifically venous thromboembolism (VTE) consisting of either one of—or both—deep vein thrombosis or pulmonary embolism (PE), is a common comorbid condition in patients with cancer.1 Isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM) is an underappreciated disease with increased VTE risk. This evidence concerns the gene IDH3A and venous thromboembolism.